for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mallinckrodt PLC

MCDG.MU

Latest Trade

0.15EUR

Change

0.00(0.00%)
0

Today's Range

0.15

 - 

0.15

52 Week Range

0.06

 - 

0.99

As of on the Over The Counter ∙ Minimum 15 minute delay

Latest Developments

Mallinckrodt Reaches Settlements With The Official Committee Of Opioid Related Creditors, The Official Committee Of Unsecured Creditors And Second Lien Noteholders

Sept 3 (Reuters) - Mallinckrodt PLC <MCDG.MU>::MALLINCKRODT REACHES SETTLEMENTS WITH THE OFFICIAL COMMITTEE OF OPIOID RELATED CREDITORS, THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS AND SECOND LIEN NOTEHOLDERS.MALLINCKRODT PLC - COMPANY TO FILE AMENDED PLAN OF REORGANIZATION TO INCORPORATE TERMS.MALLINCKRODT PLC - COMPANY ANTICIPATES COMMENCING ITS CONFIRMATION HEARING IN SEPTEMBER 2021.MALLINCKRODT PLC - AMENDED PLAN INCLUDES KEY LEGAL SETTLEMENTS THAT RESOLVE, AMONG OTHER CLAIMS, OPIOID CLAIMS BROUGHT AGAINST COMPANY..MALLINCKRODT PLC - AMENDED PLAN AND RSA PROVIDE FOR A FINANCIAL RESTRUCTURING TO REDUCE ITS TOTAL DEBT BY ABOUT $1.3 BILLION.MALLINCKRODT PLC - AMENDED PLAN IS NOW SUPPORTED BY HOLDERS OF APPROXIMATELY 84% OF COMPANY'S GUARANTEED UNSECURED NOTES.

FDA Approves Stratagraft For Treatment Of Adults With Thermal Burns

June 15 (Reuters) - FDA ::FDA APPROVES STRATAGRAFT FOR TREATMENT OF ADULTS WITH THERMAL BURNS.FDA - GRANTED APPROVAL OF STRATAGRAFT TO STRATATECH, A MALLINCKRODT COMPANY.Further company coverage: MCDG.MU. ((Reuters.Briefs@thomsonreuters.com;)).

Mallinckrodt Reports Quarterly Net Loss Per Share Of $1.81

March 10 (Reuters) - Mallinckrodt PLC <MCDG.MU>::MALLINCKRODT PLC QTRLY NET SALES $682.8 MILLION VERSUS $804.9 MILLION.MALLINCKRODT PLC QTRLY DILUTED LOSS PER SHARE FROM CONTINUING OPERATIONS $1.82.MALLINCKRODT PLC QTRLY DILUTED NET LOSS PER SHARE $1.81.

Mallinckrodt Gains Support For Restructuring Agreement From Lenders

March 10 (Reuters) - Mallinckrodt PLC <MCDG.MU>::MALLINCKRODT GAINS SUPPORT FOR ITS RESTRUCTURING SUPPORT AGREEMENT FROM LENDERS HOLDING APPROXIMATELY $1.3 BILLION OF ITS FIRST LIEN TERM LOANS.MALLINCKRODT - AGREEMENT BASED ON GIVING NEW TERM LOANS FINANCING TO REPLACE 1ST LIEN TERM LOANS, RESOLVES DISPUTE BETWEEN CO, 1ST LIEN TERM LOAN LENDERS.MALLINCKRODT - MAY REFINANCE IN FULL IN CASH ABOUT $1.9 BILLION OF CURRENTLY OUTSTANDING FIRST LIEN TERM LOANS AT PAR PRIOR TO OR ON PLAN EFFECTIVE DATE.

Mallinckrodt Files Motion In Chapter 11 Cases Of Co And Units Pending Before U.S. Bankruptcy Court

Feb 18 (Reuters) - Mallinckrodt PLC <MCDG.MU>::MALLINCKRODT - ON FEB. 17, 2021, CO FILED A MOTION IN CHAPTER 11 CASES OF CO AND UNITS PENDING BEFORE U.S. BANKRUPTCY COURT FOR DISTRICT OF DELAWARE.MALLINCKRODT -CO DISCLOSED ALTHOUGH DEBTORS HAVEN'T COMPLETED FINANCIAL REPORTING FOR 2020, AMOUNT OF MANDATORY PAYMENT IS EXPECTED TO BE ABOUT $114 MILLION.MALLINCKRODT - CO DISCLOSED AS OF END OF 2020 FISCAL YEAR, CO AND UNITS HAD APPROXIMATELY $1.07 BILLION OF UNRESTRICTED CASH ON HAND.

The Buxton Helmsley Group Announces Sufficient Shareholder Backing To Call Mallinckrodt Meeting Of Shareholders

Jan 27 (Reuters) - Buxton Helmsley Group: :THE BUXTON HELMSLEY GROUP ANNOUNCES SUFFICIENT SHAREHOLDER BACKING TO CALL MALLINCKRODT MEETING OF SHAREHOLDERS, BEGIN REALIGNING BOARD AND MANAGEMENT WITH SHAREHOLDER INTERESTS, RENEGOTIATE RESTRUCTURING PLAN.

Mallinckrodt Plc Says Has Voluntarily Initiated Chapter 11 Proceedings In U.S.

Oct 12 (Reuters) - Mallinckrodt PLC <MNK.N>::MALLINCKRODT SECURES BROAD CONSENSUS WITH KEY STAKEHOLDERS ON COMPREHENSIVE CHAPTER 11 RESTRUCTURING.PROPOSED CAPITAL STRUCTURE MODIFICATIONS WOULD REDUCE TOTAL DEBT BY APPROXIMATELY $1.3 BILLION.HAS VOLUNTARILY INITIATED CHAPTER 11 PROCEEDINGS IN U.S. BANKRUPTCY COURT FOR DISTRICT OF DELAWARE.MALLINCKRODT, ALL OF ITS SUBSIDIARIES ARE CONTINUING TO OPERATE AND SUPPLY CUSTOMERS AND PATIENTS WITH PRODUCTS AS NORMAL.REACHED AGREEMENT ON TERMS OF AMENDED PROPOSED SETTLEMENT THAT WOULD RESOLVE OPIOID-RELATED CLAIMS AGAINST CO.

Mallinckrodt Receives A Complete Response Letter From The U.S. FDA For Terlipressin

Sept 14 (Reuters) - Mallinckrodt PLC <MNK.N>::MALLINCKRODT RECEIVES A COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TERLIPRESSIN FOR THE TREATMENT OF HEPATORENAL SYNDROME TYPE 1 (HRS-1).MALLINCKRODT PLC - CRL STATED THAT, BASED ON AVAILABLE DATA, AGENCY CANNOT APPROVE TERLIPRESSIN NDA IN ITS CURRENT FORM.MALLINCKRODT PLC - CRL STATED FDA REQUIRES MORE INFORMATION TO SUPPORT POSITIVE RISK-BENEFIT PROFILE FOR TERLIPRESSIN FOR PATIENTS WITH HRS-1.MALLINCKRODT PLC - "SURPRISED BY AND DISAGREE WITH FDA'S DECISION".

Mallinckrodt Announces U.S. FDA Filing Acceptance Of Biologics License Application For Regenerative Skin Tissue Therapy

Aug 10 (Reuters) - Mallinckrodt PLC <MNK.N>::MALLINCKRODT ANNOUNCES U.S. FDA FILING ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR STRATAGRAFT® REGENERATIVE SKIN TISSUE FOR TREATMENT OF ADULTS WITH DEEP PARTIAL-THICKNESS THERMAL BURNS.MALLINCKRODT PLC - FDA GRANTED APPLICATION PRIORITY REVIEW AND ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET DATE OF FEBRUARY 2, 2021.

Mallinckrodt Q2 Loss Per Share $11.04

Aug 4 (Reuters) - Mallinckrodt PLC <MNK.N>::REPORTS EARNINGS FOR THE SECOND QUARTER 2020 AND HIGHLIGHTS PIPELINE ADVANCEMENTS.Q2 LOSS PER SHARE $11.04.Q2 ADJUSTED EARNINGS PER SHARE $1.89.Q2 REVENUE $166.5 MILLION.CONTINUES TO WORK TO RESOLVE OUTSTANDING ISSUES RELATED TO OPIOIDS, ACTHAR GEL, AND OTHER RISKS.QTRLY REPORTED GAAP NET SALES WERE IMPACTED BY RETROSPECTIVE ONE-TIME ACTHAR GEL MEDICAID LIABILITY.NORMALIZED OPERATING RESULTS ALSO DISPLAYED A CONTRACTION THIS QUARTER DUE TO COVID-19 HEALTH CRISIS.POSSIBLE THAT MALLINCKRODT PLC AND MOST OF ITS SUBSIDIARIES COULD FILE FOR CHAPTER 11 REORGANIZATION IN THE NEAR TERM.NO FINAL DETERMINATION HAS BEEN MADE WITH RESPECT TO CHATPER 11 REORGANIZATION.EXPECT CURRENT CHALLENGES TO CONTINUE IN THE BACK HALF OF THE YEAR.WORKING WITH EXTERNAL ADVISORS TO EXPLORE A RANGE OF OPTIONS.ENGAGING IN DIALOGUE WITH FINANCIAL CREDITORS AND LITIGATION CLAIMANTS AND THEIR ADVISORS.Q2 EARNINGS PER SHARE VIEW $1.34 -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up